Is ‘scarless wound healing’ applicable to glaucoma surgery?

Expert Review of Ophthalmology

Volumn 2, Issue 1, 2007, Pages 79-90

  Bruno, Christina A ^a   Fisher, Gary J ^b   Moroi, Sayoko E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

fibrosis; glaucoma; scarless wound healing; surgical outcome; trabeculectomy; wound healing

Indexed keywords

EID: 85017350890     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.1.79     Document Type: Article

References (82)

1. Ferguson MW, O’Kane S. Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. Philos. Tran. R. Soc. Lond. B. Biol. Sci. 359 (1445), 839–850 (2004).
2. Colwell AS, Longaker MT, Lorenz HP. Mammalian fetal organ regeneration. Adv. Biochem. Eng. Biotechnol. 93, 83–100 (2005).
3. Colwell AS, Longaker MT, Lorenz HP. Fetal wound healing. Front. Biosci. 8, S1240 –S1248 (2003).
4. Metcalfe AD, Ferguson AM. Harnessing wound healing and regeneration for tissue engineering. Biochem. Soc. Trans. 33, 413–417 (2005).
5. Roseborough IE, Grevious MA, Lee RC. Prevention and treatment of excessive dermal scarring. J. Natl Med. Assoc. 96 (1), 108–116 (2004).
6. Datubo-Brown DD. Keloids: a review of the literature. Br. J. Plast. Surg. 43 (1), 70–77 (1990).
7. Peled ZM, Chin GS, Liu W et al. Response to tissue injury. Clin. Plast. Surg. 27 (4), 489–500 (2000).
8. Chang L, Crowston JG, Cordeiro MF et al. The role of the immune system in conjunctival wound healing after glaucoma surgery. Surv. Ophthalmol. 45 (1), 49–68 (2000).
9. Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv. Ophthalmol. 48 (3), 314–346 (2003).
10. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90 (3), 262–267 (2006).
11. Quigley HA. Glaucoma: macrocosm to microcosm the Friedenwald lecture. Invest. Ophthalmol. Vis. Sci. 46 (8), 2662–2670 (2005).
12. Allingham RR, Damji KF, Freedman S, Moroi SE, Shafranov G, Shields MB. Shields’ Textbook of Glaucoma (5th Ed.). Lippincott Williams & Wilkins, PA, USA (2005).
13. Cantor LB, Mantravadi A, WuDunn D et al. Morphologic classification of filtering blebs after glaucoma filtration surgery: the Indiana Bleb Appearance Grading Scale. J. Glaucoma 12 (3), 266–271 (2003).
14. Picht G, Grehn F. Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr. Opin. Ophthalmol. 9 (2), 2–8 (1998).
15. Wells AP, Ashraff NN, Hall RC, Purdie G. Comparison of two clinical Bleb grading systems. Ophthalmology 113 (1), 77–83 (2006).
16. The 5-FU Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am. J. Ophthalmol. 121 (4), 349–366 (1996).
17. Katz GJ, Higginbotham EJ, Lichter PR et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. Ophthalmology 102 (9), 1263–1269 (1995).
18. Oyakhire JO, Moroi SE. Clinical and anatomical reversal of long-term hypotony maculopathy. Am. J. Ophthalmol. 137 (5), 953–955 (2004).
19. DeBry PW, Perkins TW, Heatley G et al. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch. Ophthalmol. 120 (3), 297–300 (2002).
20. Jacobi PC, Dietlein TS, Krieglstein GK. Primary trabeculectomy in young adults: long-term clinical results and factors influencing the outcome. Ophthalmic. Surg. Lasers 30 (8), 637–646 (1999).
21. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am. J. Ophthalmol. 134 (4), 481–498 (2002).
22. Berson D, Zauberman H, Landau L, Blumenthal M. Filtering operations in Africans. Am. J. Ophthalmol. 67 (3), 395–398 (1969).
23. Welsh NH. Trabeculectomy with fistula formation in the African. Br. J. Ophthalmol. 56 (1), 32–36 (1972).
24. Broadway D, Grierson I, Hitchings R. Racial differences in the results of glaucoma filtration surgery: are racial differences in the conjunctival cell profile important? Br. J. Ophthalmol. 78 (6), 466–475 (1994).
25. Atreides SP, Skuta GL, Reynolds AC. Wound healing modulation in glaucoma filtering surgery. Int. Ophthalmol. Clin. 44 (2), 61–106 (2004).
26. Skuta GL, Beeson CC, Higginbotham EJ et al. Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology 99 (3), 438–444 (1992).
27. Feldman RM, Gross RL, Spaeth GL et al. Risk factors for the development of Tenon’s capsule cysts after trabeculectomy. Ophthalmology 96 (3), 336–341 (1989).
28. Wright P. Cicatrizing conjunctivitis. Trans. Ophthalmol. Soc. UK 105 (Pt 1), 1–17 (1986).
29. Schwab IR, Linberg JV, Gioia VM et al. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 99 (2), 197–202 (1992).
30. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch. Ophthalmol. 112 (11), 1446–1454 (1994).
31. Baudouin C, Pisella PJ, Fillacier K et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 106 (3), 556–563 (1999).
32. Brandt JD, Wittpenn JR, Katz LJ et al. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am. J. Ophthalmol. 112 (3), 297–301 (1991).
33. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 96 (3), 327–335 (1989).
34. Young TL, Higginbotham EJ, Zou XL, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology 97 (11), 1423–1427 (1990).
35. Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J. Glaucoma 10 (3), 237–249 (2001).
36. Tripathi RC, Li J, Tripathi BJ et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 105 (2), 232–237 (1998).
37. Tsai JC, Feuer WJ, Parrish RK 2nd, Grajewski AL. 5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology 102 (6), 887–892 (1995).
38. Kuchtey RW, Lowder CY, Smith SD. Glaucoma in patients with ocular inflammatory disease. Ophthalmol. Clin. North. Am. 18 (3), 421–430 (2005).
39. Sung VC, Barton K. Management of inflammatory glaucomas. Curr. Opin. Ophthalmol. 15 (2), 136–140 (2004).
40. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends. Cell. Biol. 15 (11), 599–607 (2005).
41. Dang C, Ting K, Soo C et al. Fetal wound healing current perspectives. Clin. Plast. Surg. 30 (1), 13–23 (2003).
42. Bullard KM, Longaker MT, Lorenz HP. Fetal wound healing: current biology. World J. Surg. 27 (1), 54–61 (2003).
43. Chen W, Fu XB, Ge SL et al. Development of gene microarray in screening differently expressed genes in keloid and normal-control skin. Chin. Med. J. (Engl.) 117 (6), 877–881 (2004).
44. Tomic-Canic M, Brem H. Gene array technology and pathogenesis of chronic wounds. Am. J. Surg. 188 (Suppl. 1A), 67–72 (2004).
45. Masinde G, Li X, Baylink DJ et al. Isolation of wound healing/regeneration genes using restrictive fragment differential display-PCR in MRL/MPJ and C57BL/6 mice. Biochem. Biophys. Res. Commun. 330 (1), 117–122 (2005).
46. Schiller M, Javelaud D, Mauviel A. TGF-β-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J. Dermatol. Sci. 35 (2), 83–92 (2004).
47. Yang GP, Lim IJ, Phan TT et al. From scarless fetal wounds to keloids: molecular studies in wound healing. Wound Repair Regen. 11 (6), 411–418 (2003).
48. Rachfal AW, Brigstock DR. Structural and functional properties of CCN proteins. Vitam. Horm. 70, 69–103 (2005).
49. Kreis T, Vale R, (Eds). Guidebook to the Extracellular Matrix, Anchor, and Adhesion Proteins (2nd Ed.). Oxford University Press, Oxford, UK (1999).
50. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69 (3), 562–573 (2006).
51. Marneros AG, Norris JE, Watanabe S et al. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J. Invest. Dermatol. 122 (5), 1126–1132 (2004).
52. Bayat A, Bock O, Mrowietz U et al. Genetic susceptibility to keloid disease: transforming growth factor β receptor gene polymorphisms are not associated with keloid disease. Exp. Dermatol. 13 (2), 120–4 (2004).
53. Bayat A, Walter JM, Bock O et al. Genetic susceptibility to keloid disease: mutation screening of the TGFβ 3 gene. Br. J. Plast. Surg. 58 (7), 914–921 (2005).
54. Meller D, Pires RT, Mack RJ et al. Amniotic membrane transplantation for acute chemical or thermal burns. Ophthalmology 107 (5), 980–989 (2000).
55. Letko ESS, Kenyon KR, Sadeq N et al. Amniotic membrane inlay and overlay grafting for corneal epithelial defects and stromal ulcers. Arch. Ophthalmol. 119 (5), 659–663 (2001).
56. Pires RT, Chokshi A, Tseng SC. Amniotic membrane transplantation or conjunctival limbal autograft for limbal stem cell deficiency induced by 5-fluorouracil in glaucoma surgeries. Cornea 19 (3), 284–287 (2000).
57. Barton K, Budenz DL, Khaw PT, Tseng SC. Glaucoma filtration surgery using amniotic membrane transplantation. Invest. Ophthalmol. Vis. Sci. 42 (8), 1762–1768 (2001).
58. Kim JS, Kim JC, Na BK et al. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp. Eye Res. 70 (3), 329–337 (2000).
59. Lee SB, Li DQ, Tan DT et al. Suppression of TGF-β signaling in both normal conjunctival fibroblasts and pterygial body fibroblasts by amniotic membrane. Curr. Eye. Res. 20 (4), 325–334 (2000).
60. Hao Y, Ma DH, Hwang DG et al. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea 19 (3), 348–352, (2000).
61. Fujishima H, Shimazaki J, Shinozaki N, Tsubota K. Trabeculectomy with the use of amniotic membrane for uncontrollable glaucoma. Ophthalmic. Surg. Lasers 29 (5), 428–431 (1998).
62. Lu H, Mai D. Trabeculectomy combined amniotic membrane transplantation for refractory glaucoma. Yan Ke Xue Bao 19 (2), 89–91 (2003).
63. Bruno CA, Eisengart, JE, Radenbaugh PA, Moroi SE. Subconjunctival placement of human amniotic membrane during glaucoma filtration surgery. Ophthalmic. Surg. Lasers Imaging 37 (3), 190–197 (2006).
64. Budenz DL, Barton K, Tseng SC. Amniotic membrane transplantation for repair of leaking glaucoma filtering blebs. Am. J. Ophthalmol. 130 (5), 580–588 (2000).
65. Mead AL, Wong TT, Cordeiro MF et al. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest. Ophthalmol. Vis. Sci. 44 (8), 3394–3401 (2003).
66. Crooke ST. Antisense strategies. Curr. Mol. Med. 4 (5), 465–487 (2004).
67. Kashani-Sabet M. Non-viral delivery of ribozymes for cancer gene therapy. Expert. Opin. Biol. Ther. 4 (11), 1749–1755 (2004).
68. Cordeiro MF, Mead A, Ali RR et al. Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome. Gene Ther. 10 (1), 59–71 (2003).
69. Fu X, Li X, Cheng B et al. Engineered growth factors and cutaneous wound healing: success and possible questions in the past 10 years. Wound Repair Regen. 13 (2), 122–130 (2005).
70. Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 19 (4 Suppl. 3), 26–31 (2005).
71. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 (Suppl. 3), 25–33 (2005).
72. Congdon N, O'Colmain B, Klaver CC et al. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122 (4), 477–485 (2004).
73. Heier JS, Antoszyk AN, Pavan PR et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Ophthalmology 113 (4), 642.e1–642.e4 (2006).
74. Gragoudas ES, Adamis AP, Cunningham ET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351 (27), 2805–2816 (2004).
75. Stocum DL. Stem cells in regenerative biology and medicine. Wound Repair Regen. 9 (6), 429–442 (2001).
76. Jimenez PA, Jimenez SE. Tissue and cellular approaches to wound repair. Am. J. Surg. 187 (5A), 56S –64S (2004).
77. Levin LA, Ritch R, Richards JE, Borras T. Stem cell therapy for ocular disorders. Arch. Ophthalmol. 122 (4), 621–627 (2004).
78. Holland EJ, Djalilian AR, Schwartz GS. Management of aniridic keratopathy with keratolimbal allograft: a limbal stem cell transplantation technique. Ophthalmology 110 (1), 125–130 (2003).
79. Shimazaki J, Aiba M, Goto E et al. Transplantation of human limbal epithelium cultivated on amniotic membrane for the treatment of severe ocular surface disorders. Ophthalmology 109 (7), 1285–1290 (2002).
80. Eming SA, Krieg T, Davidson JM. Gene transfer in tissue repair: status, challenges and future directions. Expert. Opin. Biol. Ther. 4 (9), 1373–1386 (2004).
81. Cambridge Antibody Technology announces preliminary results of trabio Phase II/III clinical trial (2004). www.cambridgeantibody.com
82. Adapted from Asmussen PD and Sollner B. Mechanism of wound healing. In: Wound Care. Tutorial Medical Series. Hippokrates Verlag, Stuttgart, Germany (1993). www.worldwidewounds.com/2005/august/Schultz/Extrace-Matric-Acute-Chronic-Wounds.html